THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB

被引：1
作者：
Morand, E. [1 ]
Berglind, A. [2 ]
Sheytanova, T. [2 ]
Tummala, R. [2 ]
Illei, G. [3 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] AstraZeneca, Molndal, Sweden
[3] MedImmune LLC, Gaithersburg, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0001
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [31] Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
    Jagerback, Sandra
    Gomez, Alvaro
    Parodis, Ioannis
    [J]. RHEUMATOLOGY, 2024,
  • [32] PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
    Jagerback, S.
    Gomez, A.
    Parodis, I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 34
  • [33] Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus
    Piga, Matteo
    Floris, Alberto
    Cappellazzo, Giulia
    Chessa, Elisabetta
    Congia, Mattia
    Mathieu, Alessandro
    Cauli, Alberto
    [J]. ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [34] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
    David Isenberg
    Yong Li
    Stephen Wax
    David Wofsy
    Caroline Gordon
    [J]. Arthritis Research & Therapy, 16
  • [35] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
    Isenberg, David
    Li, Yong
    Wax, Stephen
    Wofsy, David
    Gordon, Caroline
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16
  • [36] EFFECTS OF ATACICEPT ON DISEASE ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: APRIL-SLE RANDOMIZED TRIAL
    Gordon, C.
    Isenberg, D.
    Li, Y.
    Wax, S.
    Wofsy, D.
    Rossi, C. Pena
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 77 - 77
  • [37] Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus
    Matteo Piga
    Alberto Floris
    Giulia Cappellazzo
    Elisabetta Chessa
    Mattia Congia
    Alessandro Mathieu
    Alberto Cauli
    [J]. Arthritis Research & Therapy, 19
  • [38] LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort
    Ugarte-Gil, Manuel Francisco
    Gamboa-Cardenas, Rocio Violeta
    Reategui-Sokolova, Cristina
    Pimentel-Quiroz, Victor Roman
    Medina, Mariela
    Elera-Fitzcarrald, Claudia
    Zevallos, Francisco
    Pastor-Asurza, Cesar Augusto
    Lofland, Jeniffer
    Zazzetti, Federico
    Karyekar, Chetan S.
    Alarcon, Graciela S.
    Perich-Campos, Risto Alfredo
    [J]. LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [39] Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
    Maslen, Toni
    Bruce, Ian N.
    D'Cruz, David
    Ianosev, Mihaela
    Bass, Damon L.
    Wilkinson, Christel
    Roth, David A.
    [J]. LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
  • [40] Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
    Furie, Richard
    Kalunian, Kenneth
    Merrill, Joan
    Abreu, Gabriel
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345